10.3 Opioids, Cannabis, Hallucinogens, and Emerging Synthetics

10.3 Opioids, Cannabis, Hallucinogens, and Emerging Synthetics

---

Opioids: Classification, Mechanisms, and Mortality Risks

Opioids are natural, semi-synthetic, or synthetic substances that bind to specific opioid receptors in the central and peripheral nervous systems, as well as the gastrointestinal tract. They are classified into three distinct categories based on their origin:

┌────────────────────────────────────────────────────────────────────────┐
│                     CLASSIFICATION OF OPIOID COMPOUNDS                 │
├──────────────────┬─────────────────────────────────────────────────────┤
│ CATEGORY         │ REPRESENTATIVE SUBSTANCES                           │
├──────────────────┼─────────────────────────────────────────────────────┤
│ 1. Natural       │ • Morphine, Codeine                                 │
│    Opiates       │ • Directly derived from the opium poppy resin       │
│                  │   (Papaver somniferum)                              │
├──────────────────┼─────────────────────────────────────────────────────┤
│ 2. Semi-Synthetic│ • Heroin (diacetylmorphine), Oxycodone (OxyContin,  │
│    Opioids       │   Percocet), Hydrocodone (Vicodin), Hydromorphone   │
│                  │   (Dilaudid), Oxymorphone (Opana), Buprenorphine    │
│                  │ • Synthesized by chemically modifying natural opiates│
├──────────────────┼─────────────────────────────────────────────────────┤
│ 3. Fully         │ • Fentanyl, Carfentanil, Methadone, Meperidine      │
│    Synthetic     │   (Demerol), Tramadol                               │
│    Opioids       │ • Completely manufactured in laboratories from base │
│                  │   chemical precursors; no poppy base utilized       │
└──────────────────┴─────────────────────────────────────────────────────┘

Mechanism of Action: The Mu-Opioid Receptor and Respiratory Suppression

There are three primary opioid receptor subtypes in the human body: Mu ($\mu$), Delta ($\delta$), and Kappa ($\kappa$). The rewarding, analgesic, and lethal properties of opioids are governed primarily by the Mu-opioid receptor:

• Analgesia & Euphoria: Mu receptors are dense in pain-modulating regions such as the periaqueductal gray of the midbrain and the dorsal horn of the spinal cord (blocking incoming pain signals) and on inhibitory GABA interneurons in the Ventral Tegmental Area (VTA). By inhibiting GABA, opioids "disinhibit" dopamine neurons, allowing a powerful torrent of dopamine to flood the Nucleus Accumbens.
• Lethal Respiratory Depression: Mu-opioid receptors are also concentrated in the respiratory rhythm-generating centers of the brainstem (specifically the pre-Bötzinger complex in the ventrolateral medulla). Agonism at these receptors blunts the brainstem's sensitivity to rising levels of carbon dioxide ($CO_2$) in the blood. In an overdose, the autonomic drive to breathe ceases, leading to respiratory arrest, anoxic brain injury, and death.

The Classic Opioid Overdose Triad

When evaluating an unconscious individual for acute opioid overdose, the clinical presentation is defined by the Opioid Overdose Triad:

1. Pinpoint Pupils (Miosis): Pupils constricted to tiny points (unless severe anoxia has set in, which can cause terminal dilation).
2. Severe Respiratory Depression: Slow, shallow breathing ($<8$ breaths per minute), agonal breathing (gasping/snoring sounds), or total apnea.
3. Unresponsiveness / Coma: Flaccid muscle tone, inability to be aroused by verbal or physical stimulation (such as a sternal rub), and cyanosis (bluish or grayish discoloration of lips and nail beds).

Opioid Withdrawal: The Agonizing Misery and the Loss-of-Tolerance Trap

Unlike alcohol or benzodiazepine withdrawal, uncomplicated opioid withdrawal is rarely fatal for an otherwise healthy adult. However, it is subjectively agonizing and deeply traumatizing. Clinical tools like the Clinical Opiate Withdrawal Scale (COWS) measure its signature symptoms:

---

Cannabis and the Endocannabinoid System

Cannabis is the most widely used psychoactive substance globally after alcohol and caffeine. It acts directly upon the human Endocannabinoid System (ECS), an intricate regulatory neuromodulatory network that oversees mood, appetite, sleep, pain sensation, and immune response.

• Endogenous Ligands: The body synthesizes its own cannabinoids on demand, primarily Anandamide (often called the "bliss molecule") and 2-Arachidonoylglycerol (2-AG).
• Receptor Subtypes:
  • CB1 Receptors: Concentrated densely in the central nervous system (cerebral cortex, hippocampus, basal ganglia, and cerebellum). Governs psychoactive effects, cognition, memory, motor coordination, and pain.
  • CB2 Receptors: Concentrated primarily in the peripheral nervous system and immune cells (spleen, tonsils, white blood cells). Modulates inflammation and immune function without causing intoxication.

Phytocannabinoids: THC vs. CBD

• Delta-9-Tetrahydrocannabinol (THC): The primary psychoactive constituent. Acts as a partial agonist at CB1 receptors, producing euphoria, relaxation, altered sensory perception, increased appetite ("munchies"), and transient short-term memory impairment. High doses can trigger acute panic, paranoia, and transient psychosis.
• Cannabidiol (CBD): A non-intoxicating compound. Demonstrates low direct affinity for CB1/CB2 receptors, acting instead as a negative allosteric modulator and interacting with serotonin (5-HT1A) and vanilloid receptors to provide anxiolytic and anti-inflammatory effects.

Cannabis Use Disorder (CUD) and Cannabis Withdrawal Syndrome

Despite the common public misconception that cannabis is entirely non-addictive, the DSM-5 formally recognizes Cannabis Use Disorder. Approximately 10% to 30% of regular cannabis users develop psychological or physical dependence. Furthermore, Cannabis Withdrawal Syndrome is clinically established, presenting within 24 to 72 hours of cessation with:

• Irritability, anger, or aggressive mood swings
• Nervousness and anxiety
• Severe sleep difficulty and vivid, bizarre dreams
• Decreased appetite and weight loss
• Physical symptoms: abdominal pain, shakiness, sweating, fever, or chills

Cannabis Hyperemesis Syndrome (CHS)

A severe clinical consequence of long-term, high-potency daily cannabis use is Cannabis Hyperemesis Syndrome (CHS). Paradoxically, while cannabis is medically recognized for anti-emetic properties at low doses, chronic hyper-stimulation of CB1 receptors in the enteric nervous system deranges gastrointestinal motility:

• Clinical Presentation: Cyclical, intractable nausea, persistent profuse vomiting, and severe colicky abdominal pain.
• The Hallmark Diagnostic Behavioral Clue: Sufferers develop a compulsive, ritualistic need for prolonged, scalding hot baths or showers, which transiently alleviates nausea by activating TRPV1 vanilloid receptors and redistributing cutaneous blood flow.
• Resolution: CHS often responds poorly to standard anti-emetic medications (e.g., ondansetron), and emergency clinicians may use other treatments for acute episodes. The definitive treatment is stopping cannabis use; symptoms typically return if use resumes.

---

Hallucinogens and Dissociatives

Hallucinogens and dissociatives represent distinct classes of substances that fundamentally alter sensory perception, cognition, and awareness of reality.

┌────────────────────────────────────────────────────────────────────────┐
│               HALLUCINOGENS VS. DISSOCIATIVE SUBSTANCES                │
├──────────────────────────┬─────────────────────────────────────────────┤
│ CLASS & SUBSTANCES       │ PHARMACOLOGICAL TARGET & CLINICAL PROFILE   │
├──────────────────────────┼─────────────────────────────────────────────┤
│ Classic Psychedelics     │ • 5-HT2A Serotonin Receptor Agonists        │
│ (Psilocybin, LSD,        │ • Profound perceptual distortions, visual   │
│  Mescaline, DMT)         │   hallucinations, synesthesia ("seeing      │
│                          │   sounds"), mystical/ego-dissolution states│
│                          │ • Low physiological toxicity; high risk of  │
│                          │   psychological panic ("bad trip") and HPPD │
├──────────────────────────┼─────────────────────────────────────────────┤
│ Entactogens / Empathogens│ • Massive Serotonin & Dopamine Releaser     │
│ (MDMA / Ecstasy / Molly) │ • Heightened empathy, emotional closeness,  │
│                          │   sensory enhancement                       │
│                          │ • Acute medical risks: severe hyperthermia, │
│                          │   severe hyponatremia (water toxicity)      │
├──────────────────────────┼─────────────────────────────────────────────┤
│ Dissociative Anesthetics │ • NMDA Glutamate Receptor Antagonists       │
│ (Ketamine, Phencyclidine │ • Sensory detachment from body and physical │
│  [PCP], Dextromethorphan)│   environment; profound analgesia (numbness)│
│                          │ • PCP Risks: Extreme combative agitation,   │
│                          │   rotary nystagmus, self-inflicted trauma   │
│                          │   due to inability to register pain         │
└──────────────────────────┴─────────────────────────────────────────────┘

Phencyclidine (PCP) and Ketamine Nuances

Peer specialists working in emergency departments or street outreach must understand the extreme behavioral risks associated with Phencyclidine (PCP, "Angel Dust"):

• NMDA Blockade: Blocks excitatory glutamate signaling, disconnecting the conscious mind from somatic sensory inputs.
• Symptom Triad: Intense, volatile agitation, vertical/rotary nystagmus (eyes rapidly jerking horizontally or vertically), and complete physical analgesia.
• Safety Hazard: Because PCP completely abolishes physical pain perception, individuals can break bones, sever tendons, or suffer deep lacerations without feeling discomfort, often struggling against physical obstacles with seemingly superhuman force. De-escalation requires a calm, low-stimulation environment with non-threatening body positioning.

---

Emerging Synthetic Threats: Fentanyl Analogs, Nitazenes, and Xylazine

The illicit drug market in North America has undergone a catastrophic structural transition from plant-derived compounds (heroin, cocaine) to ultra-potent, low-cost synthetic adulterants.

1. Illicitly Manufactured Fentanyl (IMF) and Ultra-Potent Analogs

Unlike pharmaceutical transdermal fentanyl patches, Illicitly Manufactured Fentanyl (IMF) is synthesized in clandestine labs and pressed into counterfeit prescription pills (e.g., fake "M30" oxycodone pills, counterfeit Xanax) or mixed into powder supplies.

• Potency: Fentanyl is about 50 to 100 times more potent than morphine and roughly 50 times more potent than heroin (CDC; DEA). The DEA considers 2 milligrams, about the size of a few grains of salt, a potentially lethal dose.
• Carfentanil: A veterinary opioid for sedating large animals, about 10,000 times more potent than morphine (DEA); even tiny amounts in the drug supply are extremely dangerous to the person who uses them.
• Rapid Onset ("Wooden Chest Syndrome"): Rapid, high-dose fentanyl exposure can cause chest wall and vocal cord rigidity that makes rescue breathing difficult; give naloxone promptly and get EMS on the way.

2. Nitazenes (Synthetic Benzimidazole Opioids)

As regulatory scrutiny restricted fentanyl precursors, illicit chemists developed Nitazenes (e.g., Isotonitazene, Metonitazene, Protonitazene). These synthetic opioids have no approved human medical use in the United States:

• Variable, Often Extreme Potency: Potency differs widely between nitazenes; some (such as etonitazene and N-pyrrolidino etonitazene) are estimated to be several times more potent than fentanyl, while others are similar to or weaker than fentanyl. Users rarely know which one they have.
• Naloxone Requirements: Due to exceptionally high receptor binding affinity, nitazene overdoses frequently require multiple successive doses of naloxone combined with prolonged rescue breathing.

3. Xylazine ("Tranq" / "Tranq Dope")

Xylazine is a non-opioid pharmaceutical drug developed solely as a veterinary sedative, analgesic, and muscle relaxant for large animals (horses, cattle). It is not approved for human use.

Xylazine has emerged as a pervasive adulterant in the illicit fentanyl supply, particularly throughout the Eastern and Midwestern United States, creating a lethal combination known on the street as "Tranq Dope."

┌────────────────────────────────────────────────────────────────────────┐
│                     THE CLINICAL CRISIS OF XYLAZINE                    │
├────────────────────────────────────────────────────────────────────────┤
│ 1. NON-OPIOID MECHANISM                                                │
│    Central Alpha-2 Adrenergic Agonist (similar to clonidine)           │
│    • Inhibits norepinephrine release in the brainstem                  │
│    • Causes profound sedation, bradycardia, severe hypotension         │
├────────────────────────────────────────────────────────────────────────┤
│ 2. NALOXONE NON-RESPONSIVENESS                                         │
│    • Xylazine is NOT an opioid! Naloxone does NOT reverse xylazine.    │
│    • However: Overdoses involve BOTH fentanyl and xylazine!            │
│    • ACTION: ALWAYS administer Naloxone to reverse the opioid, and     │
│      IMMEDIATELY initiate RESCUE BREATHING for xylazine sedation.      │
├────────────────────────────────────────────────────────────────────────┤
│ 3. SEVERE NECROTIC SKIN ULCERATION                                     │
│    • Causes severe peripheral vasoconstriction and localized ischemia  │
│    • Produces horrific necrotic ulcers with black eschar, slough, and  │
│      exposed bone/muscle that occur ANYWHERE on the body (not just at  │
│      injection sites; occurs even with snorting or smoking).           │
│    • High risk of osteomyelitis, systemic sepsis, and limb amputation. │
└────────────────────────────────────────────────────────────────────────┘

---

Peer Harm Reduction Navigation

Peer specialists operate at the cutting edge of evidence-based Harm Reduction, meeting individuals where they are without judgment to preserve life until recovery is chosen:

• Drug Checking Technology: Providing Fentanyl Test Strips (FTS) and Xylazine Test Strips (XTS), educating peers on proper dilution techniques to avoid false positives/negatives.
• Never Use Alone Protocols: Promoting the "Never Use Alone" national overdose prevention hotline (peer-operated hotline that stays on the phone while an individual uses and dispatches EMS only if the person becomes unresponsive).
• Rescue Breathing Priority: In the era of synthetic adulterants, rescue breathing (1 breath every 5 seconds) is the single most critical life-saving physical intervention a peer can perform alongside naloxone.
• Wound Care Navigation: Connecting peers suffering from xylazine-induced necrotic ulcerations to barrier-free medical clinics, providing clean dressing supplies, sterile saline, and non-judgmental wound management support to prevent sepsis and amputation.